Oxford Gene Technology (OGT) has raised the bar in CLL research with its SureSeq™ CLL + CNV V3 Panel. Designed in collaboration with leading experts, this upgraded panel offers lab managers a reliable solution to improve sample classification and accelerate the sample-to-result process.
The new panel includes an expanded gene list and increased probe density for greater resolution, enabling faster and more precise variant detection. The switch to internal reference DNA reduces inter-run variability, while complimentary integration with OGT’s Interpret software simplifies data analysis, even for labs without dedicated bioinformatics resources.
Benefits for Lab Managers:
- Faster Insights: Strengthened CNV detection and sample-to-result times.
- Confidence in Results: Detects CNVs with 99% concordance to FISH and down to 20% tumor content.
- User-Friendly Analysis: Complimentary NGS analysis software eliminates the need for external bioinformatics expertise.
- Optimized Workflow: Allows for a streamlined and efficient lab process, saving time and resources.
“Working with leading cancer experts, including from within the ERIC Consortium, we have identified key areas for enhancement and acted upon these to develop a product that meets the demands of busy laboratories today for CLL,” said Giulia Poloni, Product Manager at OGT. “Combining strengthened CNV calling with expansive SNV detection gives our customers faster sample insights with reduced assay times meaning they can speed up their lab’s sample-to-result process.”
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: "OGT unveils the enhanced SureSeq CLL + CNV V3 Panel for deeper insights into CLL progression"
